KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Research & Development (2016 - 2025)

Novavax has reported Research & Development over the past 16 years, most recently at $75.9 million for Q4 2025.

  • Quarterly results put Research & Development at $75.9 million for Q4 2025, down 27.31% from a year ago — trailing twelve months through Dec 2025 was $342.3 million (down 12.49% YoY), and the annual figure for FY2025 was $342.3 million, down 12.49%.
  • Research & Development for Q4 2025 was $75.9 million at Novavax, down from $98.3 million in the prior quarter.
  • Over the last five years, Research & Development for NVAX hit a ceiling of $963.0 million in Q4 2021 and a floor of $75.9 million in Q4 2025.
  • Median Research & Development over the past 5 years was $192.1 million (2023), compared with a mean of $262.0 million.
  • Biggest five-year swings in Research & Development: skyrocketed 3407.97% in 2021 and later tumbled 73.22% in 2022.
  • Novavax's Research & Development stood at $963.0 million in 2021, then tumbled by 73.22% to $257.8 million in 2022, then tumbled by 36.13% to $164.7 million in 2023, then crashed by 36.62% to $104.4 million in 2024, then fell by 27.31% to $75.9 million in 2025.
  • The last three reported values for Research & Development were $75.9 million (Q4 2025), $98.3 million (Q3 2025), and $79.2 million (Q2 2025) per Business Quant data.